Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.This report on Pirfenidone provides comprehensive ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...

Patients in the randomised, double-blind trial (NCT05321420) were selected to receive deupirfenidone 550mg, deupirfenidone 825mg, or pirfenidone at the current US Food and Drug Administration (FDA ...

Shionogi and InterMune have announced the marketing approval of pirfenidone (Pirespa) for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan, making it the first approved therapy for ...

Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis (PPF). The ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

A transatlantic Cambridge2Cambridge alliance between Qureight in the UK and Avalyn Pharma Inc in Massachusetts – is seeking ...

Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat ...